Dermira, a subsidiary of Eli Lilly and Company, operates in the dermatology sector, focusing on developing and commercializing treatments for chronic skin conditions such as hyperhidrosis (excessive sweating) and atopic dermatitis (eczema). The company primarily serves healthcare professionals and patients in the United States. Dermira's business model revolves around the research, development, and marketing of its proprietary products, including FDA-approved treatments like glycopyrronium cloth for hyperhidrosis and lebrikizumab for atopic dermatitis, which is currently in clinical trials. Revenue is generated through product sales, partnerships, and licensing agreements. The company emphasizes compliance with FDA regulations and provides extensive medical information and support to healthcare professionals.

Keywords: dermatology, hyperhidrosis, atopic dermatitis, FDA-approved, glycopyrronium cloth, lebrikizumab, clinical trials, healthcare professionals, chronic skin conditions, Eli Lilly subsidiary.